SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Blank Check IPOs (SPACS) -- Ignore unavailable to you. Want to Upgrade?


To: Glenn Petersen who wrote (1996)5/6/2009 11:15:10 AM
From: Glenn Petersen  Respond to of 3862
 
Alsius Corporation (stock symbol: [t]ALUS[/t]), originally known as Ithaka Acquisition Corp., has completed the sale of its assets to ZOLL Medical Corporation and will proceed with the liquidation of the company.

Alsius Corporation Completes Sale of Assets to ZOLL Medical Corporation

On Tuesday May 5, 2009, 9:12 pm EDT

IRVINE, Calif., May 5, 2009 (GLOBE NEWSWIRE) -- Alsius Corporation (NasdaqCM:ALUS - News) announced today that it completed the sale of its assets constituting its intravascular temperature management device business to a wholly-owned subsidiary of ZOLL Medical Corporation (NasdaqGS:ZOLL - News) for a purchase price of $12 million in cash.

William Worthen, Alsius' President and Chief Executive Officer, stated, ``The state of the financial markets made it very difficult to continue to finance Alsius as a stand-alone entity, and we believe the sale to ZOLL was the best solution for our stockholders. ZOLL's knowledge of critical care products and financial strength should ensure that Alsius' temperature management solutions continue to be supported.''

Following approval of the transaction by holders of a majority of the outstanding Alsius common stock, Alsius provided a definitive information statement to its stockholders reporting in detail on the terms of the transaction and the subsequent wind down of Alsius' affairs, including how it will use the $12 million in sales proceeds to repay indebtedness, transaction expenses and other costs. After settling all liabilities, Alsius will distribute its remaining cash to its stockholders. Alsius currently anticipates making an initial distribution of $0.30 to $0.32 per share to Alsius stockholders by the end of June 2009. After the one-year anniversary of the sale, when the period for ZOLL to make indemnity claims under the purchase agreement expires, Alsius anticipates making a final distribution to stockholders of available cash. Alsius estimates that when all distributions have been made (including the intended final distribution in approximately one year), it will return $8 million in total, or $0.36 per share, to stockholders, which exceeds its previously reported estimate of $0.34 per share. However, if liabilities are greater than estimated or if unknown liabilities are incurred, or if collections on accounts receivable are less than expected, then the amount available for distribution will be less than currently anticipated (or could be greater if liabilities are less than expected or collections exceed expectations).

Alsius intends to file a certificate of dissolution with the Delaware Secretary of State today, and in connection with the dissolution, Alsius will be changing its corporate name to ALUS Liquidation Corp. and the name of Alsius Medical Corporation, its wholly owned operating subsidiary, to ALUS Operating Liquidation Corp., as ZOLL has purchased the rights to the Alsius name and trademarks in connection with the asset sale.

Alsius also intends to notify Nasdaq today of its intent to delist its common stock from the Nasdaq Capital Market. Alsius currently anticipates that on May 15, 2009 it will file with the SEC a Form 25 relating to the delisting of the stock. Alsius expects that trading in the stock will be suspended by Nasdaq effective at the open of business on May 15, 2009, with official delisting of the stock becoming effective ten days thereafter, on May 25, 2009. Any distributions that Alsius makes will be based on shareholdings as of the close of business on the date trading in its stock ceases.

<snip>

finance.yahoo.com